Abbreviations {#nomen0010}
=============

6MWT

:   6-minute walk test

ADLs

:   Activities of daily living

AEs

:   Adverse Events

C6S

:   Chondroitin Sulphate

ERT

:   Enzyme replacement therapy

FEV~1~

:   Forced expiratory volume in one second

FEV~1~ \[%Pred\]

:   FEV1 as a percentage of predicted

FVC

:   Forced vital capacity

FVC

:   \[%Pred\]FVC as a percentage of predicted

GAG

:   Glycosaminoglycan

GALNS

:   Acetylgalactosamine-6-sulfatase

KS

:   Keratan sulphate

LSD

:   Lysosomal storage disease

MPS

:   Mucopolysaccharidosis IVA

Med nadir 3%

:   Median nadir of arterial oxygen saturations 3% from baseline

Min dip Spo2

:   Minimum dips in arterial oxygen saturations \[%\]

ODI 3%

:   Oxygen desaturation index; ≥ 3% arterial oxygen desaturations/hour
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**DOI:**[https://doi.org/10.1016/j.ymgmr.2019.100487](10.1016/j.ymgmr.2019.100487){#intref0015}**Value of the Data**•The data presented are the first comparison of enzyme replacement therapy (ERT) and non-ERT treated, in terms of the long-term decline in pulmonary function.•The data is grounded from longitudinal, standardized, repeated measurements taken from spirometry and oximetry studies.•The data is the first to report on the long-term changes in pulmonary function after an intervention such as non-invasive ventilation (NIV) and adenotonsillectomy.•These data are useful to clinicians and researchers evaluating the safety and efficacy of ERT on children with MPS IVA, especially within the context of evaluating airway respiratory changes.

1. Data {#sec1}
-------

We present original data from a retrospective, longitudinal, repeated-measures cohort study, where descriptive statistics and non-parametric correlation were performed for demographic, respiratory function and oximetry (sleep studies) variables over a study period from January 2009 to December 2018. Composite clinical endpoints used in this study for evaluating pulmonary function included spirometry variables (FEV~1~, FEV~1~ \[%Pred\] FVC, FVC \[%Pred\] and FEV1/FVC), 6MWT and oximetry variables (median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 \[%\]). The data are supplemental to our study "The Characterization of Pulmonary Function in Patients with Mucopolysaccharidoses IVA: A Longitudinal Analysis" by Kenth et al. \[[@bib1]\].

### 1.1. Baseline demographics {#sec1.1}

Thirteen children underwent ERT, whereas the non-ERT arms had 3 children. The *median age* at diagnosis was 34 months (range: 14--161; IQR 62.75). The *Presenting symptoms* included: difficulty walking (7), gibbus deformity (4), kyphoscoliosis (1) and chest-wall deformity (1). *Consanguinity* of parents was present in 12.5 \[2/16\] of patients. The median age of commencing ERT was 78 months (IQR 77.5; 10th percentile 38.4, 90th percentile 179.8). The study included 44% of males (7/16) and 56% of females (9/16). The following patterns of genetic abnormalities were present (see [Table 1](#tbl1){ref-type="table"}), heterozygous p. (Gly155Arg), c.423-11_425del14/c.860C \> T, heterozygous l113F, Y240C, heterozygous p. (l113F) and p. (R386H), heterozygous p. (arg251Ter), heterozygous p. (tyr254cys) and p. (Gln311Pro), heterozygous p. (w141×), heterozygous p. (His166Arg), heterozygous p. (A291T) with no discernible differences between the ERT treated and non-ERT treated groups. [Table 1](#tbl1){ref-type="table"} illustrates the baseline demographics, including age at diagnosis, gender, parental consanguinity, what the presenting symptom was, the genetic mutation identified, the date when ERT therapy commenced (if applicable). Data are also presented on the age at first spirometry and oximetry, the presence of obstructive sleep apnoea, whether the patients had undergone an adenotonsillectomy and the institution on non-invasive, bi-level positive pressure ventilation (BIPAP).Table 1Baseline demographics.Table 1PatientPresentationAge at Diagnosis[a](#tbl1fna){ref-type="table-fn"}ConsanguinitySexGeneticsAge ERT started[a](#tbl1fna){ref-type="table-fn"}Age at 1st spirometry[a](#tbl1fna){ref-type="table-fn"}Age at 1st oximetry[a](#tbl1fna){ref-type="table-fn"}OSAAdeno-tonsillectomyBIPAPERT treated subjectsADifficulty walking37NoFHeterozygous p.(Gly155Arg)435138NoNoNoBGibbus27NoMHomozygous p.(A291T)112105106YesYes (72, 147)YesCGibbus22N/AMNot recognised gene397139Yes(41)NoDDifficulty walking18NoMHomogenous p.(w141×)789188YesNoYesEDifficulty walking, scoliosis30N/AFN/A676767NoNoNoFChest deformity43NoFHeterozygous p.(arg251Ter)6912474YesYes (121)NoGN/A132NoMHomozygous p.(A291T)78132122YesYes (70, 142)YesHN/A35N/AFc.423-11_425del14/c.860C \> T3848YesYes (32, 51, 89)NoIFamily history, chest deformity31NoMHetero/l113F, Y240C183155155YesYes (36)NoJDifficulty walking131YesFHomozygous p. (His166Arg)175141133YesNoNoKGibbus14NoMHeterogenous p. (l113F) and p. (R386H)438224YesYes (35)NoLDifficulty walking73NoFHeterozygous p.(tyr254cys) and p. (Gln311Pro)108118105NoNoNoMGibbus, stiff joints33YesFHomozygous p.(A291T)129101100NoYes (121)NoNon ERT treated subjectsNDifficulty walking29NoMHomogenous p.(Ser264Asn)N/A10231YesNoYesOGrowth, skeletal dysplasia96N/AFHomogenous p. (Gly116Val)N/A10298YesYes (134)YesPDifficulty walking161N/AFHeterozygous p.901G \> T (Gly301Cys)N/A160N/ANoNoNo[^1][^2]

Macroglossia was present in 44% of patients (7/16), video laryngoscopy was used in 68.8% \[11/16\] of cases. Mallampati score on airway assessment was as follows: grade 1 in 25% \[4/16\] of patients, grade 2a in 37.5% \[6/16\], grade 2b in 12.5% \[2/16\], grade 3 in 7.7% \[1/16\] and no grade recorded in 18.8% \[3/16\]. Clinical symptoms of OSA was present in 68.6% (11/16) of patients. 66.7% (10/15) of patients in the study had undergone an adenotonsillectomy. The median age of adenotonsillectomy was 80 (range: 35--147; IQR 87.3; 10th percentiles 35.4, 90th percentile, 145.5) with 3 patients had repeated procedures. 31.3% (5/16) of patients were on BIPAP; the median age of commencing BIPAP was 153 months (IQR 53). 75% (12/16) of patients had undergone orthopaedic interventions, this included: C-spine fixation and halo brace in 12.5% (2/16) and 31.3% (5/16) underwent hip replacement and epiphysiodesis (8-plate).

Cardiac disease, as assessed by echocardiography was normal in 62.5% (10/16) of patients, pathology delineated included, a small patent ductus arteriosus (PDA) in 6.3% (1/16), small PDA, mild tricuspid regurgitation (TR) in 6.3% (1/16), physiological mitral (MR) in 6.3% (1/16), physiological TR + MR in 6.3% (1/16), dysplastic mitral and aortic valve in 6.3% (1/16).

### 1.2. Spirometry data {#sec1.2}

[Table 2](#tbl2){ref-type="table"} summarises the median values, range and the overall trend for the changes in pulmonary function for each of the following variables: FEV1, FEV1 \[%predicted\], FVC, FVC \[%predicted\], FEV1/FVC ratio and the six-minute walking test (6MWT). [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"} illustrate the data for each subject as longitudinal trajectories over time. Each graph is clearly labelled with the metric being assessed as well as the subject from which the data was obtained from. Linear regression was calculated where appropriate and the R^2^ and intercept (y) were also recorded.Table 2Summary of spirometry data.Table 2SubjectFEV1 \[Litres\]FEV1 \[%pred.\]FVC \[Litres\]FVC \[%pred.\]FEV1:FVC6MWT \[Metres\]A0.60 \[0.44--0.71\] {↓}82 \[61--83\]\
{→}0.71 \[0.61--0.73\] {↑}83 \[82--96\]\
{↑}0.82 \[0.72--1.0\] {↓}253 \[204--294 {↓}B0.76 \[0.59--0.04\] {↓}66 \[22--97\]\
{↓}1.04 \[0.92--1.18\] {↑}79 \[29--96\]\
{↓}0.72 \[0.53--0.92\] {↓}317 \[0--452\]\
{↓}C0.48 \[0.33--0.58\] {↑}60 \[41--64\]\
{→}0.52 \[0.36--0.62\]{↑}53 \[38--59\]\
{↑}0.94 \[0.88--0.98\] {→}180.5 \[0--246\] {↓}D0.60 \[0.41--0.67\] {↓}75 \[51--88\]\
{↓}0.8 \[0.59--0.85\] {↑}83 \[66--90\]\
{↑}0.8 \[0.4--0.97\]\
{↓}N/AE0.46 \[0.31--0.64\] {→}71 \[28--87\]\
{↓}0.51 \[0.39--0.57 {↑}72 \[43--90\]\
{↓}0.94 \[0.61--0.98\] {↓}223 \[100--349\] {↓}F0.66 \[0.64--0.67\] {↓}63 \[60--66\]\
{↓}0.96 \[0.94--0.98\] {↓}85 \[82--88\]\
{↓}0.682 \[0.68--0.684\] {↓}283 \[159--318\] {→}G0.72 \[0.57--0.84\] {→}79 \[32--101\] {↓}0.93 \[0.8--1.01\] {↑}91.5 \[47--109\] {↓}0.68 \[0.63--0.86\] {→}305 \[0--395\]\
{↓}I1.32 \[1.23--1.43\]{↑}95 \[65--101\]\
{↓}1.51 \[1.33--1.73\] {↑}88 \[79-93\
{↓}0.91 \[0.75--0.92\] {↓}150 \[0--300\]\
{↓}J2.07 \[1.7--2.25\] {↑}108 \[96--122\] {→}1.95 \[1.31--2.56\] {↑}102 \[94--114\] {→}0.91 \[0.88--1.63\] {→}241.5 \[110--442\] {↑}K0.37 \[0.2--0.4\] {↑}44 \[26--53\]\
{→}0.42 \[0.26--0.47\] {↑}46 \[29--47\]\
{↑}0.83 \[0.75--0.95\] {→}397 \[346--437\] {→}M0.66 \[0.62--0.72\] {↓}83 \[62--96\]\
{↓}0.78 \[0.7--0.96 {↑}89 \[81--90\]\
{↑}0.85 \[0.65--0.96\] {↑}N/AN0.27 \[0.22--0.34\] {↑}35 \[29-44\
{↑}0.31 \[0.25--0.37\] {↑}36 \[28--45\]\
{↑}0.88 \[0.87--0.92\] {↑}N/AO0.37 \[0.2--0.42\] {↓}49 \[22--56\]\
{↓}0.4 \[0.31--0.48\] {↓}49 \[30--56\]\
{↓}0.88 \[0.65--0.95\] {↓}N/A[^3][^4]Fig. 1Forced expiratory volume in 1 second (FEV1) changes.The above graphs demonstrates each of the individual plots where constructed to ascertain the changes in pulmonary function over time for the given variable. The starting timepoint in the ERT group was shortly after ERT therapy had commenced. Data points are in blue and a line of best fit creating a regression line was created to ascertain the overall trend of whether there was a decline or improvement. For each of the regression curve the intercept and R^2^ value is sated under the curve. Note also, the solid red and orange bars, that mark when a therapeutic intervention was undertaken. The solid vertical, red line (**−**) indicates when adenotonsillectomy was undertaken and the orange line (**−**) illustrates when NIV was instituted. There was incomplete data for some individuals, as adenotonsillectomy was undertaken prior to formal diagnosis and thus full lung function tests would not of been undertaken at the time. Subjects A to M were ERT treated and data recorded was post commencing ERT therapy; subjects N and O were not ERT treated and data was recorded after diagnosis.Fig. 1Fig. 2FEV1 as percentage of predicted, (FEV1 \[%pred\]).Fig. 2Fig. 3Forced vital capacity (FVC).Fig. 3Fig. 4FVC \[% predicted\].Fig. 4Fig. 5FEV1/FVC ratio.Fig. 5Fig. 6Six minute walk test (6MWT).The above graphs demonstrates each of the individual plots where constructed to ascertain the changes in pulmonary function over time for the given variable. Data points are in blue and a line of best fit creating a regression line was created to ascertain the overall trend of whether there was a decline or improvement. Note also, the solid red and orange bars, that mark when a therapeutic intervention was undertaken. The solid red line (−) indicates when adenotonsillectomy was undertaken and the orange line (−) illustrates when NIV was instituted.Fig. 6

### 1.3. Oximetry data {#sec1.3}

[Table 3](#tbl3){ref-type="table"} illustrates the median values, range and the overall trend for the changes in oximetry. These included data for median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 (%). [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}, [Fig. 10](#fig10){ref-type="fig"}, [Fig. 11](#fig11){ref-type="fig"}, [Fig. 12](#fig12){ref-type="fig"} illustrate the individual plots for each subject (labelled) over time. As above, linear regression was calculated where appropriate and the R^2^ and intercept (y) were also recorded.Table 3Summary of oximetry results.Table 3SubjectOximetry VariableMedian %Spo2ODI 3%Mean Nadir 3%ODI 4%Mean Nadir 4%Min dip. SpO2 (%)A97 \[95.1--98\] {→}3.5 \[2--21.5\] {→}91.9 \[87.3--93.6\] {↓}2.2 \[1--13.9\] {→}90.9 \[86.2--92.4\] {↓}83.6 \[62--90.9\] {→}B95 \[93--97\]\
{↑}13.6 \[2--51.2\] {→}87.8 \[85.6--93.5\] {↑}7.5 \[0.9--45.4\] {→}87.8 \[80--92.8\] {↑}71 \[52.5--87\]\
{↑}C94.9 \[93.6--97.5\] {→}8.3 \[0.4--24.6\] {↓}88.8 \[84.5--90.4\] {↓}6.5 \[2.6--16.7\] {→}87.9 \[84.5--89.6\] {↓}78 \[61.4--87.9\] {↓}D95 \[93.8--97\] {↑}10 \[4.6--25.7\] {↑}89.1 \[85.4--90.7\] {→}6.6 \[2.7--17.2\] {↑}87.8 \[84.6--89.8\] {↑}71.3 \[37.1--89.6\] {↓}E95.3 \[95--96.5\] {↑}2.5 \[1.5--3.8\] {↓}90.8 \[89.5--94.3\] {↑}1.6 \[0.4--3.3\] {↓}89.6 \[87.6--90.3\] {↑}85.5 \[76.6--90.8\] {→}F95.3 \[94.6--95.4\] {→}9.2 \[6.7--10.9\] {↑}89.3 \[89.2--90.8\] {↓}6.8 \[4--8\]\
{↑}88.6 \[87.9--89.6\] {↓}83.9 \[78.2--87.9\] {↑}G95.3 \[94.1--97.3\] {↑}10.5 \[8--17.8\] {↓}90.3 \[88.2--91.6\] {↑}7.8 \[5--13.5\] {→}89.1 \[87.6--90.2\] {↑}77.8 \[82.9--90.2\] {↑}H97.4 \[88.6--99\] {↓}11.9 \[5.7--21.8\] {↑}87.5 \[83.9--94.5\] {→}6.9 \[4.3--17\] {↑}86.6 \[83.1--92.6\] {→}64 \[49.9--86\]\
{→}I95.1 \[94.6--97\] {→}8.4 \[8.3--9.8\] {↓}89.8 \[89.2--92\] {↑}5.6 \[4.6--6.6\] {→}88.5 \[88.1--90.4\] {→}79 \[62.5--79.5\] {→}J97.3 \[95.8--99\] {↑}2 \[0.9--16.4\] {↓}90.1 \[89.2--94.6\] {→}1.5 \[0.4--9.3\] {↓}90.4 \[89.1--94.3\] {→}84.6 \[76--93.6\] {↑}K96.1 \[95.1--97.1\] {↓}4 \[1.7--4.9\]\
{↓}91.2 \[89.9--92.5\] {↓}2.2 \[0.8--2.6\] {→}90.7 \[88.2--91.8\] {↓}87.8 \[73.2--89.1\] {→}M95.9 \[94.3--97\] {→}8.8 \[7.2--12.9\] {→}89.3 \[88--93.2\] {↑}6.4 \[4.4--8.4\] {→}88.3 \[87--92.1\] {↑}78 \[72.8--92.1\] {↑}N98.6 \[96--100\] {→}3.5 \[0.2--10.8\] {↓}90.4 \[82.3--91.9\] {↓}2.7 \[0--7.9\]\
{→}89.1 \[87.6--91\] {↓}84.1 \[73--91\]\
{→}O94.6 \[86--98.9\] {↓}9.9 \[2--80.5\] {↓}89.3 \[88--94.4\] {→}5.8 \[0.8--89.6\] {↓}88.1 \[6.58--93.4\] {↑}83.5 \[66--89.2\] {→}[^5][^6]Fig. 7Median Spo2%.Fig. 7Fig. 8Oxygen desaturation index (ODI) 3% from baseline.Fig. 8Fig. 9Mean nadir 3%.Fig. 9Fig. 10Odi 4%.Fig. 10Fig. 11Mean nadir 4%.Fig. 11Fig. 12Minimum dips in % SpO2.Fig. 12

2. Experimental design, materials, and methods {#sec2}
----------------------------------------------

MPS IVA is associated with severe, debilitating airway and respiratory disease \[[@bib1],[@bib2]\]. The methodology employed to assess pulmonary function in this study is validated by and aligned to The American Thoracic Society \[[@bib3],[@bib4]\] and the British Thoracic Society guidance. The methodology used for oximetry as previously described by Pal et al. (2015) \[[@bib5]\], based on the American Academy of Sleep Medicine (AASM) manual for the scoring of sleep and associated events \[[@bib5],[@bib6]\]. Composite clinical endpoints used in this study for evaluating pulmonary function included spirometry variables (FEV1, FEV1 \[%Pred\] FVC, FVC \[%Pred\], FEV1/FVC); sleep studies oximetry variables (median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 (%)) and 6MWT for cardiorespiratory reserve.

MPS IVA patients treated at the Royal Manchester Children\'s Hospital, Manchester (UK) between 2009 and 2018, were identified from an existing patient database and medical records. This yielded a study group of 16 subjects for whom long-term follow-up was available at a single centre. A retrospective review was undertaken of baseline demographics, spirometry and oximetry (sleep studies), ERT and other therapeutic interventions -- including both medical and surgical measures. The data for each subject was tabulated and examined sequentially over the study period to provide a nuanced characterization of the changes in pulmonary function, evolution and natural history of disease progression. The subjects in this study included those from the MOR 100 phase 1 study (n = 5), MOR 005 phase III placebo-controlled (n = 5) and the MOR 007 trial (n = 6) \[[@bib7]\].
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[^1]: [Table 1](#tbl1){ref-type="table"} above illustrates the baseline demographics of the 16 subjects, including age at diagnosis, consanguinity, what the presenting symptom was, the genetic mutation identified, the date when ERT therapy commenced (if applicable), the age at first spirometry test and the age at first oximetry. We also record whether the child was diagnosed with obstructive sleep apnoea (OSA), if they had undergone an adenotonsillectomy and the whether the child had been instituted on non-invasive, bilevel ventilation (BIPAP).

[^2]: All ages are reported in months.

[^3]: Kenth et al. \[[@bib1]\].

[^4]: The table above illustrates the values for the 5 variables measured during spirometry for each subject - FEV1, Forced Expiratory Volume in the first second (Litres); FVC, Forced Vital Capacity, (Litres); as well as the six-minute walking test (6MWT). Median values are displayed in bold, minimum and maximum range are in square brackets. Curly braces {} denote the overall trends of the variable throughout the study: ↑, trend increased; ↓ trend decreased; →, no change. Subjects A-M (highlighted in yellow) were the ERT treated subjects, whilst subjects N and O (highlighted in pink) were untreated.

[^5]: Kenth et al. \[[@bib1]\].

[^6]: The table above illustrates the values for the 6 variables measured during oximetry testing for each subject. Median values are displayed in bold, minimum and maximum range are in square brackets. Curly braces {} denote the overall trends of the variable throughout the study: ↑, trend increased; ↓ trend decreased; →, no change in trend. ODI 3%, ≥3% arterial oxygen desaturations/hour; ODI 4%, ≥4% arterial oxygen desaturations/hour; min dip SpO2, minimum dips in oxygen saturations. Subjects A-M (highlighted in yellow) were the ERT treated subjects, whilst subjects N and O (highlighted in pink) were untreated.
